



30 October 2013

ASX ANNOUNCEMENT

IMPEDIMED NAMES INVESTIGATORS FOR PIVOTAL CLINICAL TRIAL

Professor Sheila Ridner and Dr Frank Vicini to lead clinical trial

Brisbane, Australia – **ImpediMed Limited** (ASX: IPD) (“the Company”), the world leader of bioimpedance devices for aiding in the clinical assessment of unilateral lymphoedema, announces Investigators for pivotal clinical trial. This is the first step in defining a five-year, multi-center clinical trial to study lymphoedema patient outcomes.

Professor Sheila H. Ridner, PhD, FAAN, Vanderbilt University School of Nursing, has graciously agreed to serve as the Principal Investigator for this study. Professor Ridner has been active in lymphoedema research since 2000. She has been a member of the National Lymphedema Network (NLN) since 2001. She chairs the Research Committee, and serves on the Medical Advisory Committee. She chaired the NLN subcommittee for the Lymphedema Measurement Guidelines National Accreditation Program for Breast Centers and Protocol Development. These guidelines were previously announced on ASX 28 April 2011 (US NLN posts New Position Paper around Clinical Guidelines). Professor Ridner remarked, “I am pleased to be invited to act as Principal Investigator in this study which will help improve outcomes for women suffering from lymphoedema.”

Dr Frank A. Vicini, MD, FACR, will serve as Co-Investigator. Dr Vicini is a radiation oncologist specializing in breast cancer. He has extensive experience in breast cancer clinical trial design and implementation. Dr Vicini has held multiple academic appointments, authored over 200 peer-reviewed articles and been involved in numerous clinical studies focusing on breast cancer. He is currently the Principal Investigator of several National Institutes of Health (NIH) trials with the goal of improving therapeutic outcomes for all stages of breast cancer, reducing treatment times and minimizing toxicities of healthy tissues and vital organs. He is also listed in “Best Oncology Doctors in America”. Dr Vicini commented, “I feel privileged to be involved in this important scientific study designed to improve the long-term quality of life of all women treated for breast cancer.”

President and CEO Richard Carreon stated, “We are extremely grateful to have these two prestigious investigators leading this important pivotal trial. We believe the results of this trial will help to establish L-Dex as the standard of care for all cancer patients at risk of developing lymphoedema.”

For further information contact:

**Richard Carreon, ImpediMed CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100**

For personal use only

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit www.impedimed.com.au

For personal use only